Skip to main content
Funding round raises $42M for cell therapy developer

A Series A funding round yielded $42 million for cell therapy developer Vor Biopharma. Vor, which develops targeted immunotherapies using engineered hematopoietic stem cells, will use the funds to advance its acute myeloid leukemia candidate toward the clinical trial stage.

Full Story: